Live
Endpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsPromega BlogThe Hidden Switch That Controls Lysosome FunctionFierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPOFierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3CellDNA repair drives cisplatin-induced neuronal deathCellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humansCellPersistent and transient senescent cells contribute to brain-barrier developmentCellContinuous modeling of primate embryogenesis from totipotency to early organogenesisCellRNA structure programs endogenous ADAR for precise and efficient editingFierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
Endpoints News Nov 25, 2025

FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program

FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program

Original
Body unavailable. Use the original source.